{{Drugbox
| IUPAC_name        = 2-[(3-Fluorophenyl)ethynyl]-4,6-dimethyl-3-pyridinamine
| image             = Raseglurant.svg
| CAS_number        = 757950-09-7 
| ATC_prefix        = None
| ATC_suffix        = 
| PubChem           = 10331863
| DrugBank          = 
| ChemSpiderID      = 8507323
| chemical_formula =
| C=15 | H=13 | F=1 | N=2 
| molecular_weight  = 240.276 g/mol
| SMILES = Fc2cccc(C#Cc1nc(cc(c1N)C)C)c2
| StdInChI          = 1S/C15H13FN2/c1-10-8-11(2)18-14(15(10)17)7-6-12-4-3-5-13(16)9-12/h3-5,8-9H,17H2,1-2H3
| StdInChIKey       = MEDCLNYIYBERKO-UHFFFAOYSA-N
| bioavailability   = 
| protein_bound     = 
| metabolism        = 
| elimination_half-life = 
| excretion         = 
| pregnancy_AU      =  <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US      =  <!-- A / B            / C / D / X -->
| pregnancy_category=  
| legal_AU =  <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA =  <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK =  <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US =  <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status      = 
| routes_of_administration = 
}}

'''Raseglurant''' ([[International Nonproprietary Name|INN]]) (code name '''ADX-10059''') is a [[negative allosteric modulator]] of the [[mGlu5 receptor|mGlu<sub>5</sub> receptor]] and [[chemical derivative|derivative]] of [[2-Methyl-6-(phenylethynyl)pyridine|MPEP]] which was under development by [[Addex Therapeutics]] for the treatment of [[migraine]], [[gastroesophageal reflux disease]], and [[dental anxiety]].<ref>{{cite book|title=Annual Reports in Medicinal Chemistry|url=https://books.google.com/books?id=y7GH165YoOsC&pg=PA80|date=31 December 2012|publisher=Academic Press|isbn=978-0-12-397214-9|pages=80–}}</ref><ref>{{Cite web|url=http://www.comfortfirstdentalsterling.com/dont-dodge-the-dentist-tips-for-dealing-with-dental-anxiety/|title=Don’t Dodge the Dentist – Tips for Dealing with Dental Anxiety|last=|first=|date=|language=en-US|archive-url=|archive-date=|dead-url=|access-date=2017-04-05}}</ref><ref name="SteinSteckler2010">{{cite book|author1=Murray B. Stein|author2=Thomas Steckler|title=Behavioral Neurobiology of Anxiety and Its Treatment|url=https://books.google.com/books?id=vlCV3D7J0bEC&pg=PA397|date=30 July 2010|publisher=Springer Science & Business Media|isbn=978-3-642-02912-7|pages=397–}}</ref> It reached [[Phases of clinical research|phase II]] [[clinical trial]]s for all of the aforementioned indications before being discontinued due to the observation of possible predictive signs of [[hepatotoxicity]] in patients with long-term use.<ref name="SteinSteckler2010" /><ref name="Dominguez2010">{{cite book|author=Celia Dominguez|title=Neurodegenerative Diseases|url=https://books.google.com/books?id=m3e8VHphbwcC&pg=PA120|date=18 November 2010|publisher=Springer Science & Business Media|isbn=978-3-642-16758-4|pages=120–}}</ref><ref name="Shaheen2013">{{cite book|author=Nicholas J. Shaheen|title=Benign and Neoplastic Conditions of the Esophagus, An Issue of Gastroenterology Clinics,|url=https://books.google.com/books?id=F5f6rmvFzi8C&pg=PT119|date=25 March 2013|publisher=Elsevier Health Sciences|isbn=1-4557-7175-9|pages=119–}}</ref>

==See also==
* [[Basimglurant]]
* [[Dipraglurant]]
* [[Fenobam]]
* [[Mavoglurant]]

==References==
{{Reflist|2}}

==External links==
* [http://www.addextherapeutics.com/investors/press-releases/news-details/?tx_ttnews%5Btt_news%5D%20%20=%2088&cHash=d075a6fa63acce925582f8f481fb8dc3 Development of ADX10059 Ended for Long-term Use - Addex Therapeutics]

{{Metabotropic glutamate receptor modulators}}

[[Category:Amines]]
[[Category:MGlu5 receptor antagonists]]
[[Category:Fluoroarenes]]
[[Category:Pyridines]]
[[Category:Alkynes]]


{{nervous-system-drug-stub}}